UniXell Biotechnology
Pudong
About UniXell Biotechnology
Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $52.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2026)
- Website: unixell.com
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/unixell-biotechnology-75231 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.